Table 4. Best objective response for the overall population and for those patients with ovarian cancer.
| |
Olaparib dose cohort |
|||||||
|---|---|---|---|---|---|---|---|---|
| 50 mg bid 7 day | 100 mg bid 7 day | 100 mg bid 28 day | 200 mg bid 7 day | 200 mg bid 28 day | 400 mg bid 7 day | 400 mg bid 28 day | Total | |
|
Overall population |
(n=3) |
(n=3) |
(n=4) |
(n=3) |
(n=7) |
(n=12) |
(n=12) |
(n=42) |
| Ovarian cancer patients |
(n=3) |
(n=2) |
(n=2) |
(n=2) |
(n=3) |
(n=8) |
(n=8) |
(n=26) |
|
Best objective response a, (%) | ||||||||
| Complete response | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 (7) |
| |
1 |
0 |
0 |
0 |
0 |
1 |
1 |
3 (12) |
| Partial response | 1 | 1 | 0 | 1 | 1 | 2 | 5 | 11 (26) |
| |
1 |
1 |
0 |
1 |
1 |
2 |
4 |
10 (38) |
| Stable disease | 1 | 1 | 1 | 1 | 2 | 5 | 2 | 13 (31) |
| |
1 |
0 |
0 |
1 |
1 |
4 |
1 |
8 (31) |
| Progressive disease | 0 | 1 | 2 | 1 | 2 | 3 | 4 | 13 (31) |
| |
0 |
1 |
1 |
0 |
0 |
1 |
2 |
5 (19) |
| Not evaluable/unknown | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 (5) |
a
RECIST version 1.0.